CDKN1A and hepatocellular carcinoma: Further research found that aaptamine reduces the expression of SRY-box transcription factor 9 and CDK2 in HCC cells, inhibits CDK2 kinase activity, and promotes the expression of p21 and the binding of the CDK2-cyclin D/E complex, thereby inhibiting the cell cycle.